title: Great particles [32P]chromic phosphate for treatment of solid tumors.
abstract: With the purpose of studying the effectivity of an intratumoral single dose of chromic [32P] phosphate with great particles for the treatment of solid tumors, studies of bioelimination, biodistribution and therapeutic action were carried out. Only for comparative purposes, similar studies were undertaken using a solution of sodium -32P- orthophosphate-gelatine. The results show that when sodium [32P] orthophosphate-gelatine is used, the percentage of total elimination is (85.90 +/- 8.70)% with a higher percentage in urine (64.50 +/- 13.70)% than in faeces (21.40 +/- 4.50)%. In biodistribution studies, the greater percentage is found in bone (15.54 +/- 2.21)% while only a (2.51 +/- 0.39)% remains in the tumor. When great particles chromic [32P]phosphate was intratumorally injected, we determined that the total elimination is equal (36.28 +/- 6.27)%, finding a higher amount in faeces (29.44 +/- 5.26)% than in urine (6.84 +/- 2.21)%. Biodistribution studies demonstrated that (49.82 +/- 5.41)% remains in the tumor and (9.63 +/- 4.89)% of the injected activity is found in the liver. On the other hand, when therapeutic action was evaluated, we observed that the percentage of tumor regression (P.T.R.) is 52.0% for the tumors injected with chromic [32P]phosphate and 0.0% for those injected with sodium [32P]orthophosphate-gelatine. These results show that the great particles colloid of chromic [32P]phosphate is not safe enough for the treatment of solid tumors, since it is mobilized from the injection point, delivering a high dose to the whole organism.
authors.affiliation: Radioisotope Laboratory, Facultad de Farmacia y Bioquimica, Buenos Aires, Argentina. postmast@radioqui.ff)b.uba.ar
authors.forename: M B
authors.initials: MB
authors.lastname: Zubillaga
authors.forename: J R
authors.initials: JR
authors.lastname: Boccio
authors.forename: J O
authors.initials: JO
authors.lastname: Nicolini
authors.forename: R
authors.initials: R
authors.lastname: Ughetti
authors.forename: E
authors.initials: E
authors.lastname: Lanari
authors.forename: R A
authors.initials: RA
authors.lastname: Caro
mesh_terms: D000230:Adenocarcinoma / Q000532:radiotherapy*; D000818:Animals; D017608:Chromium Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005243:Feces / Q000737:chemistry; D005260:Female; D007267:Injections; D008325:Mammary Neoplasms, Experimental / Q000532:radiotherapy*; D010710:Phosphates / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012074:Remission Induction; D016896:Treatment Outcome; D014556:Urine / Q000737:chemistry
chemical_list: D017608:Chromium Compounds; D010710:Phosphates; C509369:chromic phosphate; C018279:sodium phosphate